Estrogen receptor polymorphisms and the vascular effects of hormone therapy.
Estrogen receptor polymorphisms and the vascular effects of hormone therapy.
复制标题
雌激素受体多态性和激素治疗的血管效应。
DOI：
10.1161/atvbaha.110.215087
复制
发表时间：
2011
期刊：
影响因子：
--
通讯作者：
Herrington,David
中科院分区：
文献类型：
--
作者：
Rossouw,Jacques;Bray,Paul;Liu,Jingmin;Kooperberg,Charles;Hsia,Judith;Lewis,Cora;Cushman,Mary;Bonds,Denise;Hendrix,Susan;Papanicolaou,George;Howard,Timothy;Herrington,David
目的测试是否雌激素受体多态性修改绝经后激素治疗的生物标志物和冠心病事件，中风，或静脉thromboembolis.Methods和ResultsThe设计的风险的影响是一个巢式病例对照研究在妇女健康倡议试验绝经后激素治疗。这项研究包括了前4年的所有病例：359例冠心病，248例中风和217例静脉血栓栓塞。对6种雌激素受体-α多态性和1种雌激素受体-β多态性进行基因分型;在基线和随机分组后1年测量8种已知受激素治疗影响的生物标志物。这些多态性与血管事件的风险无关，也没有改变激素治疗引起的冠心病、中风或静脉血栓栓塞的风险增加。然而，雌激素受体-1IVS1的纤溶酶-抗纤溶酶对激素治疗的反应降低，（内含子编号1）-354（相互作用P <0.0001，多重比较校正P =0.014）和促性腺激素受体-1IVS1-1415结论雌激素受体多态性降低绝经后激素治疗对纤溶酶-抗纤溶酶的影响，凝血和纤维蛋白溶解的标志物。然而，筛选雌激素受体多态性以确定心血管不良结局风险较低的女性不太可能在决定激素治疗时有用。
ObjectiveTo test whether estrogen receptor polymorphisms modify the effects of postmenopausal hormone therapy on biomarkers and on risk of coronary heart disease events, stroke, or venous thromboembolism.Methods and ResultsThe design was a nested case-control study in the Women's Health Initiative trials of postmenopausal hormone therapy. The study included all cases in the first 4 years: 359 cases of coronary heart disease, 248 of stroke, and 217 of venous thromboembolism. Sixestrogen receptor-αpolymorphisms and 1estrogen receptor-βpolymorphism were genotyped; 8 biomarkers known to be affected by hormone therapy were measured at baseline and 1 year after randomization. The polymorphisms were not associated with risk of vascular events and did not modify the increased risks of coronary heart disease, stroke, or venous thromboembolism due to hormone therapy. However, a reduced response of plasmin-antiplasmin to hormone therapy was noted forestrogen receptor-1IVS1 (intron number 1)-354 (interactionP<0.0001, corrected for multiple comparisonsP=0.014) andestrogen receptor-1IVS1-1415 (interactionP<0.0001, correctedP=0.014).ConclusionEstrogen receptor polymorphisms reduce the effect of postmenopausal hormone therapy on plasmin-antiplasmin, a marker of coagulation and fibrinolysis. However, screening for estrogen receptor polymorphisms to identify women at less risk of adverse cardiovascular outcomes is not likely to be useful in making decisions about hormone therapy treatment.